Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said

You may also be interested in...

Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea

Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.

Korea’s Health Ministry Selects 43 Innovative Companies For Tax/Funding Benefits

Tax credits, priority for government projects and expanded funding opportunities will support 42 Korean firms and Korea-heavy Otsuka Pharmaceutical with R&D expansion

Pfizer’s Second Market For Targeted Lung Cancer Drug Xalkori Is Korea

After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts